Literature DB >> 10599328

Raynaud's phenomenon and vascular disease in systemic sclerosis.

S Generini1, M Matucci Cerinic.   

Abstract

Raynaud's phenomenon (RP) is very often the first manifestation of SSc preceding the onset of all the other signs and symptoms of the disease. Two structures are involved in the pathogenesis of RP: the endothelium and the peripheral nervous system (PNS). The hypothesis is that SSc modifies consistently the activity of both these systems leading eventually to RP. The disease, through the injury to the endothelium, jeopardizes the basilar endothelial-dependent vascular tone control. An increase of endothelin, a potent endothelial-derived vasoconstrictor, and the reduction of nitric oxide, one of the main endothelial vasodilators, are two key events involved in the genesis of RP. The PNS is also targeted by the disease as demonstrated by the high incidence of neuropathy in SSc patients. A marked reduction of sensory fibres has been detected in SSc skin. Thus, the involvement of nerve terminals reduces the vasodilatory, endothelial dependent or independent, potential of the neuropeptides released by sensory nerve endings. Indeed, an increased sensitivity of alpha 2 adrenoceptors mediated vasoconstriction has been shown in SSc skin. The complex vasodilatory network formed by the interaction between the endothelium and the PNS seems greatly damaged by SSc leading inesorably toward vascular tone dysfunction clinically evident as RP.

Entities:  

Mesh:

Year:  1999        PMID: 10599328     DOI: 10.1007/978-1-4615-4857-7_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  Neurosonological and cognitive screening for evaluation of systemic sclerosis patients.

Authors:  B R Sakr; R E Rabea; A M Aboulfotooh; N A Kishk
Journal:  Clin Rheumatol       Date:  2019-02-26       Impact factor: 2.980

2.  The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function.

Authors:  Alma Cypiene; Aleksandras Laucevicius; Algirdas Venalis; Jolanta Dadoniene; Ligita Ryliskyte; Zaneta Petrulioniene; Milda Kovaite; Jonas Gintautas
Journal:  Clin Rheumatol       Date:  2008-07-25       Impact factor: 2.980

3.  An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.

Authors:  Magalys Vitiello; Adriana Abuchar; Néstor Santana; Luis Dehesa; Francisco A Kerdel
Journal:  J Clin Aesthet Dermatol       Date:  2012-07

4.  Increased circulating fibrinogen-like protein 2 in patients with systemic sclerosis.

Authors:  Koichi Yanaba; Yoshihide Asano; Shinji Noda; Kaname Akamata; Naohiko Aozasa; Takashi Taniguchi; Takehiro Takahashi; Yohei Ichimura; Tetsuo Toyama; Hayakazu Sumida; Yoshihiro Kuwano; Yayoi Tada; Makoto Sugaya; Takafumi Kadono; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2012-09-16       Impact factor: 2.980

5.  Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.

Authors:  Chiew-Gek Khor; Xena Lung-Fang Chen; Ting-Syuan Lin; Cheng-Hsun Lu; Song-Chou Hsieh
Journal:  Clin Rheumatol       Date:  2014-04-12       Impact factor: 2.980

Review 6.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 7.  Neurogenic Appendicitis: A Reappraisal of the Clinicopathological Features and Pathogenesis.

Authors:  Mahmoud Rezk Abdelwahed Hussein; Ali Al Bshabshe; Ahmed Abdelsatar Elhakeem; Mahmoud Kamal Elsamman
Journal:  Diagnostics (Basel)       Date:  2022-06-03

Review 8.  Serotonin paracrine signaling in tissue fibrosis.

Authors:  Derek A Mann; Fiona Oakley
Journal:  Biochim Biophys Acta       Date:  2012-09-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.